Residual Scope: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia AALL1521

Badgett, James (PI)
Radulescu, Vlad (Former PI)
Wagner, Lars (Former PI)

Pediatrics

1 Finished

1 results

Finished
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia AALL1521
Badgett, J. (PI), Radulescu, V. (Former PI) & Wagner, L. (Former PI)
Public Health Institute
12/1/16 → 1/25/26
Project: Research project